---
layout: default
title: Ganciclovir
parent: 僅模型預測 (L5)
nav_order: 205
evidence_level: L5
indication_count: 0
---

# Ganciclovir
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The data-report skill applies to CLI output scenarios, which doesn't match this task. Proceeding directly with the structured report generation per the system prompt format.

---

# Ganciclovir: Antiviral Agent (CMV) — No Repurposing Predictions Available

## One-Sentence Summary

Ganciclovir is a synthetic guanosine analogue antiviral agent, primarily used for the prevention and treatment of cytomegalovirus (CMV) infections in immunocompromised patients (e.g., following organ transplantation or in HIV/AIDS).
The current Evidence Pack contains **no TxGNN-predicted new indications**, as the prediction pipeline produced no output for this candidate.
Critical data gaps in safety and mechanism-of-action fields prevent a complete repurposing evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | CMV retinitis; CMV disease prophylaxis in immunocompromised patients (general medical knowledge — no Danish authorisation on record) |
| Predicted New Indication | None available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no predictions generated |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for Ganciclovir in this Evidence Pack; mechanistic applicability to a new indication therefore cannot be assessed at this stage.

From general pharmacological knowledge, Ganciclovir (DrugBank: DB01004) is a prodrug activated preferentially in CMV-infected cells. Viral UL97 kinase phosphorylates the drug to ganciclovir-monophosphate; cellular kinases subsequently produce the triphosphate form, which competitively inhibits viral DNA polymerase (pUL54) and, upon incorporation into viral DNA, terminates chain elongation. Selectivity stems from the preferential phosphorylation step in infected cells. The mechanism-of-action field in this Evidence Pack is unpopulated and requires retrieval from the DrugBank API (Data Gap DG002).

Should the TxGNN pipeline be re-run successfully, potential repurposing directions might include other herpesvirus-family infections (EBV, HHV-6, HHV-8), or disease contexts where CMV reactivation plays a documented pathological role — such as glioblastoma, inflammatory bowel disease, or post-transplant lymphoproliferative disease. However, these directions are speculative until model output is available.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication.

*(No predicted_indications entry is present in this Evidence Pack; therefore no associated trial data can be extracted.)*

---

## Literature Evidence

Currently no related literature available for a repurposing indication.

*(No predicted_indications entry is present in this Evidence Pack; therefore no associated publication data can be extracted.)*

---

## Denmark Market Information

No marketing authorisations are on record for Ganciclovir in Denmark according to the data provided.

| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|-------------------------------|--------------|-------------|---------------------|
| — | — | — | No authorisations found |

> **Note for prescribers:** Ganciclovir (Cymevene®) holds a centralised EMA marketing authorisation valid across the EU/EEA. The absence of a local Danish registry record may reflect a data gap rather than a true absence of availability. Clinicians should verify current status directly via the [EMA product database](https://www.ema.europa.eu/en/medicines) and the Laegemiddelstyrelsen product register.

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

> Both the key warnings and contraindications fields are unpopulated in this Evidence Pack (Data Gap DG001 — Blocking severity). The TFDA/Laegemiddelstyrelsen SmPC PDF must be retrieved and parsed before any safety-dependent evaluation step can proceed. Known class-level concerns include significant myelosuppression (neutropenia, thrombocytopenia), reproductive toxicity, and carcinogenic potential, but these require formal SmPC confirmation before clinical use in any new indication.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Ganciclovir contains no TxGNN repurposing predictions and is missing two critical data fields (safety profile, mechanism of action), making it impossible to conduct a meaningful repurposing evaluation or safety pre-screen at this time.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** for Ganciclovir (DB01004) to generate disease repurposing candidates — without model output, this entire evaluation workflow cannot advance
- **Retrieve MOA data from DrugBank API** (Data Gap DG002 — High severity) to enable mechanistic plausibility analysis
- **Download and parse the SmPC PDF** from Laegemiddelstyrelsen / EMA to populate key warnings and contraindications (Data Gap DG001 — Blocking severity, required before S1 safety pre-screening)
- **Confirm Denmark/EU market status** by cross-checking the EMA centralised authorisation register for Cymevene® and any valganciclovir (prodrug) authorisations that may be clinically relevant
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

